Banyan BioInnovations Capital Fund I LP

The absence of prior EDGAR filings from this manager means this is either a first institutional fund or a vehicle launched by GPs new to SEC reporting; the 06b exemption (pre-existing relationships only) signals the team is building from a closed network rather than launching a broad brand-led raise, typical of GPs converting from operating roles or internal angel syndicates into formalized vehicles.

A June 2026 filing follows the typical late-Q2 window for biotech-focused venture funds, aligning with the post-earnings season when corporate venture and large-cap pharma budgets are often reset; this timing also captures the tail end of biotech valuation resets and consolidation appetites that typically drive LP LP capital calls in life sciences.

Before commitment, verify whether any of the five GPs—particularly Geoffrey Meyerson or Andrew Meyerson (likely family-connected based on shared surname)—have controlling-GP carve-outs, key-person removal provisions, or co-investment rights that could create LP governance friction, and confirm whether the $102M target is a binding hard cap or a soft fundraising range subject to oversubscription.